A Neuromedin B Receptor Blockade Inhibits the Growth of Human Oral Cancer Cells.
- Author:
Hyun Joo PARK
1
;
Jae Hoon JEON
;
Mi Kyoung KIM
;
Mi Heon RYU
;
Yong Deok KIM
;
Soo Kyung BAE
;
Moon Kyoung BAE
Author Information
1. Department of Oral Physiology, School of Dentistry, Pusan National University, Yangsan 626-870, South Korea. mkbae@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
human oral cancer cells;
neuromedin B receptor;
PD168368;
apoptosis;
cell cycle arrest
- MeSH:
Apoptosis;
Carcinoma, Squamous Cell;
Cell Cycle Checkpoints;
Humans;
Mouth Neoplasms*;
Receptors, Bombesin*
- From:International Journal of Oral Biology
2014;39(1):1-7
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Neuromedin B (NMB) acts as a growth factor or a morphogen and plays a role in cancer progression. Indeed, the NMB receptor (NMB-R) is overexpressed in different types of tumors. In our current study, we investigated the involvement of NMB-R in the proliferation of oral cancer cells. Human oral squamous cell carcinoma (SCC) and human oral cancer cells, SCC-25 cells were found to be NMB-R-positive. The NMB-R antagonist PD168368 inhibited the proliferation of SCC-25 cells and reduced their colony formation capacity. We also found that PD168368 induced the cell cycle arrest and apoptosis of SCC-25 cells in a dose-/time-dependent manner. Overall, this antitumor activity of PD168368 in human oral cancer cells suggests that NMB-R is a potential target for the future prevention and treatment of human cancers.
